Abstract
Colorectal cancer (CRC) is a molecular and clinically heterogeneous disease. In 2015, the Colorectal Cancer Subtyping Consortium classified CRC into four consensus molecular subtypes (CMS), but these CMS have had little impact on the clinical practice. The purpose of this study is to deepen into the molecular characterization of CRC. A novel approach, based on probabilistic graphical models (PGM) and sparse k-means-Consensus Cluster layer analyses was applied in order to functionally characterize CRC tumors. First, PGM was used to functionally characterize CRC, and then, sparse k-means-Consensus cluster was used to explore layers of biological information and establish classifications. To this aim, gene expression and clinical data of 805 CRC samples from three databases were analyzed. Tree different layers based on biological features were identified: adhesion, immune and molecular. The adhesion layer divided patients into high and low adhesion groups, with prognostic value. The immune layer divided patients into immune-high and immune-low groups, according to the expression of immune-related genes. The molecular layer established four molecular groups related to stem cells, metabolism, Wnt signalling pathway and extracellular functions. Immune-high patients, with a higher expression of immune-related genes and genes involved in viral mimicry response may be benefit for immunotherapy and viral mimicry-related therapies. Additionally, several possible therapeutic targets have been identified in each molecular group. Therefore, this improved CRC classification could be useful for searching new therapeutic targets and specific therapeutic strategies in CRC disease.
Simple summary Colorectal cancer is a heterogeneous disease. Several efforts have been done to characterize this heterogeneity but they have not impact in clinic. In this work, we used a novel analysis approach based on identifying layers of information using expression data from colorectal tumors and characterize three different layers of information: one layer related to adhesion with prognostic value, one related to immune characteristics and one related to molecular features. The molecular layer divided colorectal tumors in stem cell, Wnt, metabolic, and extracellular groups. These molecular groups suggested some possible therapeutic targets for each group. Additionally, immune characteristics divided tumors in tumors with a high expression of immune and viral mimicry response genes and with a low expression, suggesting immunotherapy and viral mimicry related therapies as suitable for these immune-high patients.
Competing Interest Statement
AG-P and JAFV are shareholders of Biomedica Molecular Medicine SL. EL-C is an employee of Biomedica Molecular Medicine. The other authors declare that there are no conflicts of interest.
Funding Statement
EL-C is supported by the Spanish Economy and Competitiveness Ministry (PTQ2018-009760). This research was funded by Jesus Antolin Garciarena fellowship from IdiPAZ
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Three colorectal tumor gene expression databases (GSE17536, GSE35896, and GSE39582) were analyzed. Data is available at synapse platform (https://www.synapse.org/#!Synapse:syn2623706/wiki/67246).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.